NCT00945490

Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018

Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0018

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 500 (actual)
• Sponsor: Nymox Corporation · Industry
• Sex: Male
• Age: 45 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the safety and efficacy of a 2.5 mg dose of NX-1207 for the treatment of BPH (benign prostatic hyperplasia) as compared to placebo.

Conditions

• Benign Prostatic Hyperplasia (BPH)

Interventions

Type	Name	Description
DRUG	NX-1207	Single intraprostatic injection of 2.5 mg NX-1207
DRUG	Placebo	Single intraprostatic injection of placebo

Timeline

• Start date: 2009-05-01
• Primary completion: 2014-05-01
• Completion: 2014-05-01
• First posted: 2009-07-24
• Last updated: 2017-03-10

Locations

35 sites across 1 country: United States